FDA
-
-
-
-
-
-
-
Biohaven reports positive patient data for autoimmune disease drugs
-
-
-
-
-
-
-
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Biohaven shares cancer drug trial results at European oncology meeting
-
-
-
-
-
-
-
BofA Securities Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral
-
-
-
-
-
-
-
FDA rejects Biohaven drug application for rare brain disorder
-
-
-
-
-
-
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at BTIG
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
-
325,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

